Literature DB >> 24927073

The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites.

Katelyn R Keyloun1, Molly C Reid1, Ryan Choi1, Yifan Song2, Anna M W Fox1, Heidi K Hillesland1, Zhongsheng Zhang2, RamaSubbaRao Vidadala3, Ethan A Merritt2, Audrey O T Lau4, Dustin J Maly3, Erkang Fan2, Lynn K Barrett1, Wesley C Van Voorhis1, Kayode K Ojo1.   

Abstract

Specific roles of individual CDPKs vary, but in general they mediate essential biological functions necessary for parasite survival. A comparative analysis of the structure-activity relationships (SAR) of Neospora caninum, Eimeria tenella and Babesia bovis calcium-dependent protein kinases (CDPKs) together with those of Plasmodium falciparum, Cryptosporidium parvum and Toxoplasma gondii was performed by screening against 333 bumped kinase inhibitors (BKIs). Structural modelling and experimental data revealed that residues other than the gatekeeper influence compound-protein interactions resulting in distinct sensitivity profiles. We subsequently defined potential amino-acid structural influences within the ATP-binding cavity for each orthologue necessary for consideration in the development of broad-spectrum apicomplexan CDPK inhibitors. Although the BKI library was developed for specific inhibition of glycine gatekeeper CDPKs combined with low inhibition of threonine gatekeeper human SRC kinase, some library compounds exhibit activity against serine- or threonine-containing CDPKs. Divergent BKI sensitivity of CDPK homologues could be explained on the basis of differences in the size and orientation of the hydrophobic pocket and specific variation at other amino-acid positions within the ATP-binding cavity. In particular, BbCDPK4 and PfCDPK1 are sensitive to a larger fraction of compounds than EtCDPK1 despite the presence of a threonine gatekeeper in all three CDPKs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24927073      PMCID: PMC4390295          DOI: 10.1017/S0031182014000857

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  26 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  A review of the penetration of antibiotics into CSF and its clinical significance.

Authors:  R Norrby
Journal:  Scand J Infect Dis Suppl       Date:  1978

3.  Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.

Authors:  Eric T Larson; Kayode K Ojo; Ryan C Murphy; Steven M Johnson; Zhongsheng Zhang; Jessica E Kim; David J Leibly; Anna M W Fox; Molly C Reid; Edward J Dale; B Gayani K Perera; Jae Kim; Stephen N Hewitt; Wim G J Hol; Christophe L M J Verlinde; Erkang Fan; Wesley C Van Voorhis; Dustin J Maly; Ethan A Merritt
Journal:  J Med Chem       Date:  2012-03-13       Impact factor: 7.446

4.  Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes.

Authors:  Christopher Mehlin; Erica Boni; Frederick S Buckner; Linnea Engel; Tiffany Feist; Michael H Gelb; Lutfiyah Haji; David Kim; Colleen Liu; Natascha Mueller; Peter J Myler; J T Reddy; Joshua N Sampson; E Subramanian; Wesley C Van Voorhis; Elizabeth Worthey; Frank Zucker; Wim G J Hol
Journal:  Mol Biochem Parasitol       Date:  2006-04-18       Impact factor: 1.759

5.  Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii.

Authors:  Ryan C Murphy; Kayode K Ojo; Eric T Larson; Alejandro Castellanos-Gonzalez; B Gayani K Perera; Katelyn R Keyloun; Jessica E Kim; Janhavi G Bhandari; Natascha R Muller; Christophe L M J Verlinde; A Clinton White; Ethan A Merritt; Wesley C Van Voorhis; Dustin J Maly
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

6.  High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.

Authors:  Markus A Seeliger; Matthew Young; M Nidanie Henderson; Patricia Pellicena; David S King; Arnold M Falick; John Kuriyan
Journal:  Protein Sci       Date:  2005-10-31       Impact factor: 6.725

7.  Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.

Authors:  Steven M Johnson; Ryan C Murphy; Jennifer A Geiger; Amy E DeRocher; Zhongsheng Zhang; Kayode K Ojo; Eric T Larson; B Gayani K Perera; Edward J Dale; Panqing He; Molly C Reid; Anna M W Fox; Natascha R Mueller; Ethan A Merritt; Erkang Fan; Marilyn Parsons; Wesley C Van Voorhis; Dustin J Maly
Journal:  J Med Chem       Date:  2012-02-27       Impact factor: 7.446

8.  Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

Authors:  C Katlama; S De Wit; E O'Doherty; M Van Glabeke; N Clumeck
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

Review 9.  The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues.

Authors:  D S Reeves; P J Wilkinson
Journal:  Infection       Date:  1979       Impact factor: 3.553

10.  Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors.

Authors:  Kayode K Ojo; Claudia Pfander; Natascha R Mueller; Charlotte Burstroem; Eric T Larson; Cassie M Bryan; Anna M W Fox; Molly C Reid; Steven M Johnson; Ryan C Murphy; Mark Kennedy; Henning Mann; David J Leibly; Stephen N Hewitt; Christophe L M J Verlinde; Stefan Kappe; Ethan A Merritt; Dustin J Maly; Oliver Billker; Wesley C Van Voorhis
Journal:  J Clin Invest       Date:  2012-05-08       Impact factor: 14.808

View more
  28 in total

1.  A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice.

Authors:  Alejandro Castellanos-Gonzalez; Hayley Sparks; Samantha Nava; Wenlin Huang; Zhongsheng Zhang; Kasey Rivas; Matthew A Hulverson; Lynn K Barrett; Kayode K Ojo; Erkang Fan; Wesley C Van Voorhis; Arthur Clinton White
Journal:  J Infect Dis       Date:  2016-10-12       Impact factor: 5.226

2.  Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.

Authors:  Deborah A Schaefer; Dana P Betzer; Kylie D Smith; Zachary G Millman; Hannah C Michalski; Sarah E Menchaca; Jennifer A Zambriski; Kayode K Ojo; Matthew A Hulverson; Samuel L M Arnold; Kasey L Rivas; Rama S R Vidadala; Wenlin Huang; Lynn K Barrett; Dustin J Maly; Erkang Fan; Wesley C Van Voorhis; Michael W Riggs
Journal:  J Infect Dis       Date:  2016-10-17       Impact factor: 5.226

Review 3.  Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.

Authors:  Wesley C Van Voorhis; J Stone Doggett; Marilyn Parsons; Matthew A Hulverson; Ryan Choi; Samuel L M Arnold; Michael W Riggs; Andrew Hemphill; Daniel K Howe; Robert H Mealey; Audrey O T Lau; Ethan A Merritt; Dustin J Maly; Erkang Fan; Kayode K Ojo
Journal:  Exp Parasitol       Date:  2017-01-05       Impact factor: 2.011

4.  In vitro growth inhibition of Theileria equi by bumped kinase inhibitors.

Authors:  Fernanda Gimenez; Siddra A Hines; Ryan Evanoff; Kayode K Ojo; Wesley C Van Voorhis; Dustin J Maly; Rama S R Vidadala; Robert H Mealey
Journal:  Vet Parasitol       Date:  2018-01-01       Impact factor: 2.738

5.  Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Authors:  Rama Subba Rao Vidadala; Kasey L Rivas; Kayode K Ojo; Matthew A Hulverson; Jennifer A Zambriski; Igor Bruzual; Tracey L Schultz; Wenlin Huang; Zhongsheng Zhang; Suzanne Scheele; Amy E DeRocher; Ryan Choi; Lynn K Barrett; Latha Kallur Siddaramaiah; Wim G J Hol; Erkang Fan; Ethan A Merritt; Marilyn Parsons; Gail Freiberg; Kennan Marsh; Dale J Kempf; Vern B Carruthers; Nina Isoherranen; J Stone Doggett; Wesley C Van Voorhis; Dustin J Maly
Journal:  J Med Chem       Date:  2016-07-01       Impact factor: 7.446

6.  Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.

Authors:  Suzanne Scheele; Jennifer A Geiger; Amy E DeRocher; Ryan Choi; Tess R Smith; Matthew A Hulverson; Rama Subba Rao Vidadala; Lynn K Barrett; Dustin J Maly; Ethan A Merritt; Kayode K Ojo; Wesley C Van Voorhis; Marilyn Parsons
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

7.  Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Vreni Balmer; Dustin J Maly; Erkang Fan; Luis-Miguel Ortega-Mora; Kayode K Ojo; Wesley C Van Voorhis; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

8.  7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.

Authors:  Rama S R Vidadala; Martin Golkowski; Matthew A Hulverson; Ryan Choi; Molly C McCloskey; Grant R Whitman; Wenlin Huang; Samuel L M Arnold; Lynn K Barrett; Erkang Fan; Ethan A Merritt; Wesley C Van Voorhis; Kayode K Ojo; Dustin J Maly
Journal:  ACS Infect Dis       Date:  2018-03-16       Impact factor: 5.084

Review 9.  Drug target identification in protozoan parasites.

Authors:  Joachim Müller; Andrew Hemphill
Journal:  Expert Opin Drug Discov       Date:  2016-06-16       Impact factor: 6.098

10.  Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

Authors:  Matthew A Hulverson; Sumiti Vinayak; Ryan Choi; Deborah A Schaefer; Alejandro Castellanos-Gonzalez; Rama S R Vidadala; Carrie F Brooks; Gillian T Herbert; Dana P Betzer; Grant R Whitman; Hayley N Sparks; Samuel L M Arnold; Kasey L Rivas; Lynn K Barrett; A Clinton White; Dustin J Maly; Michael W Riggs; Boris Striepen; Wesley C Van Voorhis; Kayode K Ojo
Journal:  J Infect Dis       Date:  2017-04-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.